Core Insights - Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative treatments for serious autoimmune and inflammatory diseases [1][3] - The company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, and will hold one-on-one investor meetings on the same day [1] Company Overview - Zura is developing dual-pathway antibodies aimed at addressing unmet needs in autoimmune and inflammatory diseases [3] - The company's pipeline includes candidates targeting immune system imbalances to enhance efficacy, safety, and dosing convenience [3] Product Pipeline - Zura's lead product candidate, tibulizumab (ZB-106), is currently in two Phase 2 clinical studies: TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis [4] - Additional candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for various autoimmune and inflammatory conditions [4]

Core Insights - Sitryx Therapeutics has regained rights to SYX-1042, an itaconate mimetic for chronic autoimmune and inflammatory diseases, from Eli Lilly due to Lilly's portfolio reprioritization [1][2] - The Phase 1 study of SYX-1042, which was initiated by Lilly, has been completed successfully, providing a phase 2-ready data package for Sitryx to evaluate further development options [2][3] - Sitryx plans to review the clinical and preclinical data to determine the optimal path forward for SYX-1042, expressing gratitude to Lilly for their collaboration [3] Company Overview - Sitryx is a clinical-stage biopharmaceutical company focused on developing novel oral therapies aimed at restoring immune balance in autoimmune and inflammatory diseases [4] - The company has a diverse pipeline of small molecule candidates targeting significant autoimmune indications with high unmet needs, including its lead candidate SYX-5219 for atopic dermatitis [4] - Established in 2018, Sitryx has raised $85 million from various investors, including SV Health Investors and Eli Lilly, and is headquartered in Oxford, UK [5]